Davidson Kempner Capital Management LP Has $28.69 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Davidson Kempner Capital Management LP grew its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 152.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,765,485 shares of the company’s stock after purchasing an additional 1,066,150 shares during the period. Davidson Kempner Capital Management LP owned approximately 0.16% of Teva Pharmaceutical Industries worth $28,689,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of TEVA. Janney Montgomery Scott LLC raised its stake in shares of Teva Pharmaceutical Industries by 13.6% in the first quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock valued at $19,366,000 after acquiring an additional 164,614 shares during the last quarter. QRG Capital Management Inc. boosted its stake in Teva Pharmaceutical Industries by 53.7% in the first quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after purchasing an additional 50,247 shares in the last quarter. Capital Wealth Planning LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $2,169,000. Public Employees Retirement Association of Colorado increased its stake in shares of Teva Pharmaceutical Industries by 1,382.8% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 255,826 shares of the company’s stock valued at $2,671,000 after buying an additional 238,573 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of Teva Pharmaceutical Industries by 12.0% in the first quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock valued at $8,613,000 after buying an additional 65,529 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insiders Place Their Bets

In other news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares of the company’s stock, valued at approximately $777,285. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TEVA. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Wednesday, July 10th. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd. UBS Group lifted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Barclays upped their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $18.89.

Teva Pharmaceutical Industries Trading Down 1.4 %

Teva Pharmaceutical Industries stock opened at $17.51 on Monday. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The firm has a 50-day moving average of $17.66 and a 200-day moving average of $16.11. The company has a market cap of $19.83 billion, a price-to-earnings ratio of -42.71, a P/E/G ratio of 1.26 and a beta of 0.88. Teva Pharmaceutical Industries Limited has a one year low of $8.06 and a one year high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.